Syndax Pharmaceuticals, Inc.

DB:1T3 Stock Report

Market Cap: €1.3b

Syndax Pharmaceuticals Valuation

Is 1T3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1T3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1T3's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1T3's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1T3?

Key metric: As 1T3 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1T3. This is calculated by dividing 1T3's market cap by their current book value.
What is 1T3's PB Ratio?
PB Ratio3.8x
BookUS$366.43m
Market CapUS$1.41b

Price to Book Ratio vs Peers

How does 1T3's PB Ratio compare to its peers?

The above table shows the PB ratio for 1T3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average13.1x
BIO3 Biotest
2x29.3%€1.3b
FYB Formycon
1.5x32.4%€882.8m
VSC 4SC
45.8xn/a€50.2m
HPHA Heidelberg Pharma
3.1x-33.0%€110.9m
1T3 Syndax Pharmaceuticals
3.8x24.4%€1.4b

Price-To-Book vs Peers: 1T3 is good value based on its Price-To-Book Ratio (3.8x) compared to the peer average (13.1x).

Price to Book Ratio vs Industry

How does 1T3's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1T3 3.8xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1T3 is expensive based on its Price-To-Book Ratio (3.8x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 1T3's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1T3 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1T3's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1T3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€15.30
€35.38
+131.2%
21.6%€46.49€17.08n/a14
Nov ’25€17.00
€32.66
+92.1%
15.8%€41.56€21.24n/a14
Oct ’25€16.90
€32.03
+89.5%
16.2%€41.00€20.96n/a13
Sep ’25€17.90
€32.03
+79.0%
16.2%€41.00€20.96n/a13
Aug ’25€20.60
€31.81
+54.4%
16.2%€41.63€21.28n/a13
Jul ’25€18.70
€32.39
+73.2%
16.2%€42.01€21.47n/a13
Jun ’25€17.40
€31.46
+80.8%
16.8%€41.43€21.18n/a12
May ’25€19.40
€32.64
+68.2%
17.4%€42.07€21.50n/a12
Apr ’25€20.80
€32.20
+54.8%
17.1%€41.20€21.06n/a12
Mar ’25€21.20
€32.68
+54.2%
17.0%€41.53€21.22n/a12
Feb ’25€18.60
€32.62
+75.4%
16.8%€41.65€21.29n/a12
Jan ’25€19.10
€32.34
+69.3%
14.0%€40.86€25.42n/a13
Dec ’24€14.90
€32.22
+116.3%
12.8%€39.50€25.72n/a12
Nov ’24€13.00
€33.43
+157.2%
12.6%€40.69€26.49€17.0012
Oct ’24€14.40
€33.82
+134.8%
7.4%€38.91€29.65€16.9010
Sep ’24€17.60
€33.29
+89.1%
8.0%€38.62€29.43€17.9010
Aug ’24€19.00
€32.90
+73.2%
7.4%€37.86€28.84€20.6010
Jul ’24€19.20
€30.82
+60.5%
6.5%€34.04€28.52€18.708
Jun ’24€18.30
€31.23
+70.7%
6.8%€34.21€28.67€17.409
May ’24€18.10
€31.11
+71.9%
4.4%€34.11€29.50€19.408
Apr ’24€18.60
€31.11
+67.3%
4.4%€34.11€29.50€20.808
Mar ’24€23.40
€31.78
+35.8%
9.7%€38.45€27.20€21.209
Feb ’24€25.80
€31.75
+23.1%
10.6%€37.80€26.74€18.609
Jan ’24€22.60
€31.46
+39.2%
8.7%€37.02€27.53€19.107
Dec ’23€22.40
€32.21
+43.8%
6.1%€34.92€28.93€14.907
Nov ’23€22.60
€30.51
+35.0%
7.9%€34.29€25.47€13.007

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%